Trial Profile
A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients, With or Without the CCR5 Delta-32 Mutation, Pre-treated With Cyclophosphamide
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Oct 2021
Price :
$35
*
At a glance
- Drugs SB 728 T (Primary) ; Cyclophosphamide
- Indications HIV-1 infections
- Focus Adverse reactions
- 08 Apr 2019 Status changed from active, no longer recruiting to completed.
- 13 Nov 2018 Planned End Date changed from 1 Jan 2019 to 1 Feb 2019.
- 21 Aug 2017 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.